Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00322764 | Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression | PHASE2 | COMPLETED | 80 | — | — | Mar 1, 2006 | - | Nov 9, 2007 | 11 | United States |
| Name | Type | Description |
|---|---|---|
| Uridine | DRUG | - |
Inclusion Criteria: 1. DSM-IV-TR diagnosis of Bipolar I Depression 2. 18 to 65 years of age, inclusive 3. Depressive phase, as measured by MADRS greater than or equal to 20 at Screening and Day1 4. Duration of current depressive episode of at least four weeks by Day 1 5. Competent to give informed ...